<DOC>
	<DOCNO>NCT00384085</DOCNO>
	<brief_summary>The primary objective : - To demonstrate superiority Lantus plus stepwise addition mealtime ApidraÂ® ( Lantus/Apidra-3 ) versus twice-daily Premixed insulin base proportion patient achieve target glycemic control ( measure hemoglobin A1c [ HbA1c ] &lt; 7.0 % ) Week 60 - To demonstrate noninferiority Lantus plus addition 1 mealtime Apidra injection ( Lantus/Apidra-1 ) versus twice-daily Premixed insulin base reduction Baseline Week 60 HbA1c</brief_summary>
	<brief_title>Insulin Glargine `` All Target '' Trial</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<criteria>Male female patient 30 80 year age Body Mass Index &lt; 45 kg/m2 With Type 2 diabetes mellitus least 2 year With HbA1c level screen &gt; 7.5 % &gt; 7.0 % randomization On stable dual triple oral therapy least 3 month Oral agent 2 3 follow class : SU repaglinide , biguanide , TZD , willing able perform selfmonitoring BG Females childbearing potentially require willing able use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>